These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of niacin and Niaspan on HDL lipoprotein cellular SR-BI-mediated cholesterol efflux.
    Author: Morgan JM, de la Llera-Moya M, Capuzzi DM.
    Journal: J Clin Lipidol; 2007 Dec; 1(6):614-9. PubMed ID: 21291703.
    Abstract:
    BACKGROUND: Niacin, the lipid-regulating agent with the longest therapeutic experience, has been demonstrated to both raise high-density lipoprotein cholesterol (HDL-C) levels and to diminish the risk of atherosclerosis and its vascular complications. OBJECTIVE: The present study was carried out to explore niacin's effect on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux, a component of reverse cholesterol transport, using an in vitro model system. METHODS: Thirty frozen samples from a large randomized, multicenter trial comparing crystalline niacin, extended-release niacin (Niaspan), and placebo were analyzed for SR-BI efflux. RESULTS: Both the extended-release and crystalline niacin demonstrated significant increases in HDL-C (approximately 50%) over baseline values compared to the placebo group (14%). This was associated with a significant increase in SR-BI efflux of 2.7% and 3.4% for extended-release niacin and niacin, respectively, compared to placebo (0.4%). Although, there was no relationship between HDL-C and SR-BI efflux at baseline or at the end of treatment, there was a linear relation between the changes in HDL-C and SR-BI efflux (r = 0.58, P < 0.002). CONCLUSION: This study suggests that niacin has a beneficial effect on SR-BI efflux that is related to the change in level of HDL-C.
    [Abstract] [Full Text] [Related] [New Search]